Edap Tms S.a. (EDAP) is a Medical - Devices company in the Healthcare sector, currently trading at $3.30. It has a SharesGrow Score of 31/100, indicating a weak investment profile with 1 out of 7 criteria passed.
Analyst consensus target is EDAP = $2 (-39.4% upside).
Valuation: EDAP trades at a trailing Price-to-Earnings (P/E) of -3.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.21.
Financials: revenue is $71M, +8.7%/yr average growth. Net income is $29M (loss), growing at -222%/yr. Net profit margin is -41.5% (negative). Gross margin is 42.5% (-1.4 pp trend).
Balance sheet: total debt is $28M against $17M equity (Debt-to-Equity (D/E) ratio 1.68, leveraged). Current ratio is 1.31 (adequate). Debt-to-assets is 41.2%. Total assets: $67M.
Analyst outlook: 5 / 8 analysts rate EDAP as buy (63%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 72/100 (Pass), Growth 40/100 (Partial), Past 0/100 (Fail), Health 17/100 (Fail), Moat 39/100 (Fail), Future 37/100 (Fail), Income 10/100 (Fail).
